Table 2. Thrombogenic biomarker levels during antiplatelet therapy.

Variables	CLPD group (n=20)	CILO group (n=20)	PUFA group (n=20)	p
vWF:Ag (IU/dL)
Aspirin monotherapy	159.7±34.1	150.1±33.0	135.9±24.6	0.074
Combination therapy	147.6±41.2	140.8±31.0	135.0±28.6	0.506
LS mean difference	12.1	9.3	1.6
95% CI of difference	−1.6 to 25.8	0.3 to 18.2	−8.3 to 11.5
p value	0.081	0.044	0.734
Fibrinogen (mg/dL)
Aspirin monotherapy	316.8±60.9	289.7±78.5	304.5±45.4	0.402
Combination therapy	291.9±60.7	278.4±60.7	293.7±53.7	0.664
LS mean difference	24.9	11.4	10.8
95% CI of difference	5.4 to 44.4	−4.5 to 27.2	−11.7 to 33.3
p value	0.015	0.151	0.328
D-dimer (ng/mL)
Aspirin monotherapy	722.5±1108.3	448.5±307.0	336.0±175.8	0.183
Combination therapy	725.5±1203.6	465.0±281.2	338.0±106.1	0.227
LS mean difference	−3.0	−16.5	−2.0
95% CI of difference	−123.5 to 117.5	−93.6 to 60.6	−74.2 to 70.2
p value	0.959	0.659	0.954
hs-CRP (µg/dL)
Aspirin monotherapy	107.5±111.0	83.0±50.1	145.5±125.9	0.153
Combination therapy	117.8±117.8	83.0±61.6	142.0±180.5	0.358
LS mean difference	33.5	13.8	49.1
95% CI of difference	−79.1 to 61.1	−23.8 to 28.9	−99.3 to 106.3
p value	0.791	1.000	0.944

Values are presented as mean±standard deviation or number. CLPD: clopidogrel, CILO: cilostazol, PUFA: omega-3 polyunsaturated fatty acid, vWF:Ag: von Willebrand factor antigen, LS: least mean square, hs-CRP: high sensitivity C-reactive protein